<DOC>
	<DOCNO>NCT01709084</DOCNO>
	<brief_summary>The purpose study demonstrate noninferiority ( new treatment equivalent standard treatment ) term percentage patient plasma human immunodeficiency virus-type 1 ( HIV-1 ) ribonucleic acid ( RNA ) level less 400 copy per mL 48 week randomize treatment tenofovir disoproxil fumarate/emtricitabine/rilpivirine ( TDF/FTC/RPV ) versus TDF/FTC/efavirenz ( TDF/FTC/EFV ) .</brief_summary>
	<brief_title>A Clinical Trial Comparing Efficacy Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine ( TDF/FTC/RPV ) Versus TDF/FTC/Efavirenz ( TDF/FTC/EFV ) Patients With Undetectable Plasma HIV-1 RNA Current First-line Treatment</brief_title>
	<detailed_description>This 48-week , multicenter ( study conduct multiple site ) , multinational ( conduct different country ) , open-label ( people know identity intervention ) , randomize ( study medication assign chance ) study ass whether tenofovir disoproxil fumarate/emtricitabine/rilpivirine ( TDF/FTC/RPV ) show noninferior response rate human immunodeficiency virus-type 1 ( HIV-1 ) ribonucleic acid ( RNA ) suppression le 400 copy per mL , compare TDF/FTC/efavirenz ( TDF/FTC/EFV ) . The study consist 3 phase include , screen phase ( 6 week ) , treatment phase ( 48 week ) , follow phase ( 30 35 day last dose study medication ) . During 48 week treatment phase , patient currently HIV-1 RNA suppression le 50 copy per mL first-line antiretroviral regimen , randomize 1:1 ratio , 2 group , ie , Group 1 ( treatment group ) Group 2 ( control group ) . Both group receive fix dose combination ( FDC ) regimen ( ie , FDC tablet : one tablet per day ) either TDF/FTC/RPV Group 1 TDF/FTC/EFV Group 2 . Patients return study visit Week 4 , 12 , 24 , 36 , 48 treatment period , every 24 week thereafter extend treatment period last patient Week 48 ( treatment discontinuation ) visit . Safety evaluation adverse event , clinical laboratory ( central local ) test , electrocardiogram , vital sign , physical examination perform throughout study . The treatment duration patient expect 48 108 week .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Documented human immunodeficiency virustype 1 ( HIV1 ) infection Patients receive first line highly active antiretroviral therapy ( HAART ) least 1 year screen visit Patients take ARV combination least 8 week screen visit expect continue regimen throughout screen period . Patients prefer change current HAART regimen reason simplification and/or toxicity nucleoside/nucleotide reverse transcriptase inhibitor ( N [ ] RTI ) Plasma HIV1 RNA le 50 copy per mL CD4+ cell count high 200 per mm3 screen visit Agrees protocoldefined use effective contraception History virologic failure ( 2 consecutive plasma HIV1 ribonucleic acid ( RNA ) equal 400 copy per mL ) previous current ART History immunologic failure ( 2 consecutive CD4+ cell count HAART treatment fall preHAART level ) History primary N [ ] RTI NNRTI mutation Has previously document HIV2 infection Significantly decrease hepatic function hepatic insufficiency diagnose acute clinical viral hepatitis Diagnosed Mycobacterium tuberculosis infection Severe laboratory abnormality Creatinine clearance le 50 mL per minute Addicted drug , include alcohol recreational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Human immunodeficiency virus-type 1 infection</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Infectious disease</keyword>
	<keyword>Ribonucleic acid</keyword>
	<keyword>RNA</keyword>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Rilpivirine</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Edurant</keyword>
	<keyword>TMC278</keyword>
	<keyword>R278474</keyword>
	<keyword>Fixed dose combination</keyword>
</DOC>